AR and cancer: A prominent example is enzalutamide (Xtandi®), a second-generation AR antagonist showing robust anti-cancer activity with an expanding application to patient care for both castration-resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC) (9,10).